Similar articles

• Anti-Rh17 (anti-Hr0): a rare diagnostic and management problem.

  Salamat N, Bhatti FA, Hussain A, Ziaullah. Salamat N, et al. J Pak Med Assoc. 2004 Apr;54(4):215-8. J Pak Med Assoc. 2004. PMID: 15242002 No abstract available.
• Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study).

  Ovali F, Samanci N, Dağoğlu T. Ovali F, et al. Pediatr Res. 1996 May;39(5):831-4. doi: 10.1203/00006450-199605000-00015. Pediatr Res. 1996. PMID: 8726237 Clinical Trial.
• [Phototherapy and treatment with phenobarbital in hemolytic disease of newborn due to Rh-incompatibility].

  Menzel K, Schambach K, Töpke B. Menzel K, et al. Acta Paediatr Acad Sci Hung. 1974;15(3-4):333-9. Acta Paediatr Acad Sci Hung. 1974. PMID: 4219868 German. No abstract available.
• Statement from the consensus conference on anti-D prophylaxis. 7 and 8 April 1997. The Royal College of Physicians of Edinburgh. The Royal College of Obstetricians and Gynaecologists, UK.

  [No authors listed] [No authors listed] Vox Sang. 1998;74(2):127-8. doi: 10.1046/j.1423-0410.1998.7420127.x. Vox Sang. 1998. PMID: 9501413 Review. No abstract available.
• The safety of RhIG in the prevention of haemolytic disease of the newborn.

  Hirose TG, Mays DA. Hirose TG, et al. J Obstet Gynaecol. 2007 Aug;27(6):545-57. doi: 10.1080/01443610701469941. J Obstet Gynaecol. 2007. PMID: 17896248 Review. No abstract available.